Achieving a pathologic complete response was associated with a twofold higher 5-year overall survival rate among patients with localized pancreatic adenocarcinoma who ...

Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results from ...

Primary chemotherapy has become the standard treatment of inflammatory and locally advanced breast cancer (LABC) and has more recently been extended to the management of patients with operable disease ...

A paper published in the British Medical Journal, authored by FDA staff, compares content from FDA's complete response letter for a rejected drug, with the subsequent press release by drug developers.

Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol. Without ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...

A sequential and prospectively maintained database at the Royal Marsden Hospital, London, was retrospectively searched for women who had received neoadjuvant chemotherapy for primary operable breast ...

Neoadjuvant systemic therapy leads to significant clinical and pathological response in patients with HER2-positive breast cancers. Significant predictors of pathological response include HER2 protein ...

Adverse Event Reporting in Publications Compared With Sponsor Database for Cancer Clinical Trials Between 1998 and 2004, 586 patients were treated for colorectal LMs in one institution. Of these, 38 ...

Please provide your email address to receive an email when new articles are posted on . Talazoparib (Talzenna, Pfizer), a poly(ADP)-ribose polymerase (PARP) inhibitor, also appeared generally ...